{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T10:17:21Z","timestamp":1783765041290,"version":"3.55.0"},"reference-count":45,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,11,18]],"date-time":"2022-11-18T00:00:00Z","timestamp":1668729600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100006407","name":"Natural Science Foundation of Henan Province","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006407","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100019331","name":"Henan Medical Science and Technique Foundation","doi-asserted-by":"publisher","award":["2018020007"],"award-info":[{"award-number":["2018020007"]}],"id":[{"id":"10.13039\/501100019331","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>We compared the differential expression of 15 markers in PTCL (Peripheral T-cell lymphoma) subtypes and T-CUS (T-cell clones of uncertain significance), and summarized the specific immunophenotype profiles of each subtype and its impact on prognosis. PD-1 and CD10 are diagnostic markers for AITL (angioimmunoblastic T-cell lymphoma). To avoid confusion with T-CUS of benign clones, it is recommended to define AITL as bounded by PD-1+%&amp;gt;38.01 and\/or CD10+%&amp;gt;7.46. T cell-derived ENKTL-N (extranodal NKT cell lymphoma) specifically expresses CD56. ALCL (anaplastic large cell lymphoma) characteristically expresses CD30 and HLA-DR. PTCL-NOS (peripheral T-cell lymphoma unspecified) still lacks a relatively specific phenotype and is prone to loss of basic lineage markers CD3, CD5, and CD7. The determination of T-CUS can be verified by the overall assessment of the bone marrow and a certain period of follow-up. The clustering results showed that the expression of 8 specific markers was significantly different among the 5 groups, suggesting that a combination of related markers can be analyzed in the identification of PTCLs subtypes. The study explores the advantages of TRBC1 combined with CD45RA\/CD45RO in detecting T cell clonality, which can efficiently and sensitively analyze multiple target T cell populations at the same time. The sensitivity of PB to replace BM to monitor the tumor burden or MRD (minimal residual disease) of PTCLs is as high as 85.71%, which can relieve the huge pressure of clinical sampling and improve patient compliance. CD7, CD38, and Ki-67 are prognostic indicators for AITL. CD3 and CD8 on PTCL-NOS, and CD56 and HLA-DR on ENKTL-N have prognostic role. This study supports and validates the current classification of PTCL subtypes and establishes an immunophenotypic profile that can be used for precise diagnosis. The important clinical value of PTCLs immunophenotype in routine classification diagnosis, clonality confirmation, prognosis prediction, and treatment target selection was emphasized.<\/jats:p>","DOI":"10.3389\/fimmu.2022.1008695","type":"journal-article","created":{"date-parts":[[2022,11,18]],"date-time":"2022-11-18T06:20:14Z","timestamp":1668752414000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":22,"title":["Differential diagnosis and identification of prognostic markers for peripheral T-cell lymphoma subtypes based on flow cytometry immunophenotype profiles"],"prefix":"10.3389","volume":"13","author":[{"given":"Qiyao","family":"Pu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Qiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuke","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueyan","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ran","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongyao","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoqian","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiwei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baohong","family":"Yue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,11,18]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-05-231548","article-title":"Peripheral T-cell lymphoma","volume":"117","author":"Foss","year":"2011","journal-title":"Blood"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2008.16.4558","article-title":"International peripheral T-cell and natural Killer\/T-cell lymphoma study: Pathology findings and clinical outcomes","volume":"26","author":"Vose","year":"2008","journal-title":"J Clin Oncol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-03-1306","article-title":"T-Cell non-Hodgkin lymphoma","volume":"107","author":"Rizvi","year":"2006","journal-title":"Blood"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-08-105759","article-title":"Clinical, biologic, and pathologic features in 157 patients with angioimmunoblastic T-cell lymphoma treated within the groupe d'etude des lymphomes de l'adulte (Gela) trials","volume":"111","author":"Mourad","year":"2008","journal-title":"Blood"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(12)60035-x","article-title":"Hodgkin's lymphoma in adults","volume":"380","author":"Townsend","year":"2012","journal-title":"Lancet"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-07-2947","article-title":"Molecular profiling of diffuse Large b-cell lymphoma identifies robust subtypes including one characterized by host inflammatory response","volume":"105","author":"Monti","year":"2005","journal-title":"Blood"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25224","article-title":"Cutaneous b-cell lymphomas: 2019 update on diagnosis, risk stratification, and management","volume":"93","author":"Wilcox","year":"2018","journal-title":"Am J Hematol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-01-134270","article-title":"Alk- anaplastic Large-cell lymphoma is clinically and immunophenotypically different from both alk+ alcl and peripheral T-cell lymphoma, not otherwise specified: Report from the international peripheral T-cell lymphoma project","volume":"111","author":"Savage","year":"2008","journal-title":"Blood"},{"key":"B9","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1186\/s13148-020-00962-x","article-title":"Epigenetic alterations and advancement of treatment in peripheral T-cell lymphoma","volume":"12","author":"Zhang","year":"2020","journal-title":"Clin Epigenet"},{"key":"B10","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/s11899-020-00561-w","article-title":"Brentuximab vedotin in the treatment of peripheral T cell lymphoma and cutaneous T cell lymphoma","volume":"15","author":"Shea","year":"2020","journal-title":"Curr Hematol Malig Rep"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-08-692566","article-title":"Peripheral T-cell lymphoma, not otherwise specified","volume":"129","author":"Broccoli","year":"2017","journal-title":"Blood"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1038\/s41379-020-0568-2","article-title":"T-Cell clones of uncertain significance are highly prevalent and show close resemblance to T-cell Large granular lymphocytic leukemia. implications for laboratory diagnostics","volume":"33","author":"Shi","year":"2020","journal-title":"Mod Pathol"},{"key":"B13","first-page":"78","article-title":"Loss of activation-induced Cd45ro with maintenance of Cd45ra expression during prolonged culture of T cells and nk cells","volume":"74","author":"Warren","year":"1991","journal-title":"Immunology"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22041817","article-title":"Emerging role of T-cell receptor constant B chain-1 (Trbc1) expression in the flow cytometric diagnosis of T-cell malignancies","volume":"22","author":"Horna","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1002\/cyto.a.24272","article-title":"Omip 071: A 31-parameter flow cytometry panel for in-depth immunophenotyping of human T-cell subsets using surface markers","volume":"99","author":"Wang","year":"2021","journal-title":"Cytometry A"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the world health organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13174379","article-title":"Anti-Trbc1 antibody-based flow cytometric detection of T-cell clonality: Standardization of sample preparation and diagnostic implementation","volume":"13","author":"Mu\u00f1oz-Garc\u00eda","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26303","article-title":"Restricted Trbc1 expression: A clonality marker for circulating s\u00e9zary cells","volume":"96","author":"Tintle","year":"2021","journal-title":"Am J Hematol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1038\/nm.4444","article-title":"Targeting the T cell receptor B-chain constant region for immunotherapy of T cell malignancies","volume":"23","author":"Maciocia","year":"2017","journal-title":"Nat Med"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0125373","article-title":"Quantifying distribution of flow cytometric tcr-v\u03b2 usage with economic statistics","volume":"10","author":"van der Geest","year":"2015","journal-title":"PloS One"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1093\/ajcp\/aqw015","article-title":"Clinical experience with modified, single-tube T-cell receptor v\u03b2 flow cytometry analysis for T-cell clonality","volume":"145","author":"Wu","year":"2016","journal-title":"Am J Clin Pathol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1136\/jcp.2009.069336","article-title":"Tcr-vbeta flow cytometric analysis of peripheral blood for assessing clonality and disease burden in patients with T cell Large granular lymphocyte leukaemia","volume":"63","author":"Feng","year":"2010","journal-title":"J Clin Pathol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2015.12.005","article-title":"Re-examining the nature and function of self-reactive T cells","volume":"37","author":"Richards","year":"2016","journal-title":"Trends Immunol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1038\/nature03725","article-title":"Regulation of immunity by self-reactive T cells","volume":"435","author":"Kronenberg","year":"2005","journal-title":"Nature"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019002610","article-title":"Blood monitoring of circulating tumor plasma cells by next generation flow in multiple myeloma after therapy","volume":"134","author":"Sanoja-Flores","year":"2019","journal-title":"Blood"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.918487","article-title":"Comprehensive analysis and summary of the value of immunophenotypes of mature nk cell tumors for differential diagnosis, treatment, and prognosis","volume":"13","author":"Pu","year":"2022","journal-title":"Front Immunol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminhematol.2018.02.010","article-title":"Comprehensive characterization of circulating and bone marrow-derived multiple myeloma cells at minimal residual disease","volume":"55","author":"Waldschmidt","year":"2018","journal-title":"Semin Hematol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s40164-020-00188-w","article-title":"Molecular insights into pathogenesis and targeted therapy of peripheral T cell lymphoma","volume":"9","author":"Xie","year":"2020","journal-title":"Exp Hematol Oncol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2017-0524","article-title":"Recent advances in the treatment of peripheral T-cell lymphoma","volume":"23","author":"Laribi","year":"2018","journal-title":"Oncologist"},{"key":"B30","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/s13045-020-00889-z","article-title":"Biomarker-driven management strategies for peripheral T cell lymphoma","volume":"13","author":"Mulvey","year":"2020","journal-title":"J Hematol Oncol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(18)32984-2","article-title":"Brentuximab vedotin with chemotherapy for Cd30-positive peripheral T-cell lymphoma (Echelon-2): A global, double-blind, randomised, phase 3 trial","volume":"393","author":"Horwitz","year":"2019","journal-title":"Lancet"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2017-0263","article-title":"Brentuximab vedotin therapy for Cd30-positive cutaneous T-cell lymphoma: A targeted approach to management","volume":"13","author":"Scarisbrick","year":"2017","journal-title":"Future Oncol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1097\/CCO.0b013e32834bb8a7","article-title":"Cd30-targeted antibody therapy","volume":"23","author":"Younes","year":"2011","journal-title":"Curr Opin Oncol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-015-2359-2","article-title":"Cd38 expression predicts poor prognosis and might be a potential therapy target in extranodal Nk\/T cell lymphoma, nasal type","volume":"94","author":"Wang","year":"2015","journal-title":"Ann Hematol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"52","DOI":"10.20892\/j.issn.2095-3941.2020.0400","article-title":"Updating targets for natural Killer\/T-cell lymphoma immunotherapy","volume":"18","author":"Xue","year":"2021","journal-title":"Cancer Biol Med"},{"key":"B36","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1016\/j.clml.2019.03.022","article-title":"Phase ii study of the pd-1 inhibitor pembrolizumab for the treatment of relapsed or refractory mature T-cell lymphoma","volume":"19","author":"Barta","year":"2019","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"B37","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s13045-018-0559-7","article-title":"Activity of pembrolizumab in Relapsed\/Refractory Nk\/T-cell lymphoma","volume":"11","author":"Li","year":"2018","journal-title":"J Hematol Oncol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1200\/jco.20.01342","article-title":"Anti-Cd30 car-T cell therapy in relapsed and refractory Hodgkin lymphoma","volume":"38","author":"Ramos","year":"2020","journal-title":"J Clin Oncol"},{"key":"B39","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1186\/s13045-019-0801-y","article-title":"Targeting T cell malignancies using car-based immunotherapy: Challenges and potential solutions","volume":"12","author":"Fleischer","year":"2019","journal-title":"J Hematol Oncol"},{"key":"B40","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1186\/s12885-019-5415-9","article-title":"Challenges of driving Cd30-directed car-T cells to the clinic","volume":"19","author":"Grover","year":"2019","journal-title":"BMC Cancer"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-01-761320","article-title":"Cd7-edited T cells expressing a Cd7-specific car for the therapy of T-cell malignancies","volume":"130","author":"Gomes-Silva","year":"2017","journal-title":"Blood"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020002396","article-title":"T Follicular helper phenotype predicts response to histone deacetylase inhibitors in Relapsed\/Refractory peripheral T-cell lymphoma","volume":"4","author":"Ghione","year":"2020","journal-title":"Blood Adv"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-09-872549","article-title":"Genetic drivers of oncogenic pathways in molecular subgroups of peripheral T-cell lymphoma","volume":"133","author":"Heavican","year":"2019","journal-title":"Blood"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019000779","article-title":"Reproducing the molecular subclassification of peripheral T-cell lymphoma-nos by immunohistochemistry","volume":"134","author":"Amador","year":"2019","journal-title":"Blood"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2012.268","article-title":"Successful treatment with anti-cc chemokine receptor 4 moab of relapsed adult T-cell Leukemia\/Lymphoma after umbilical cord blood transplantation","volume":"48","author":"Ito","year":"2013","journal-title":"Bone Marrow Transplant"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.1008695\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,18]],"date-time":"2022-11-18T06:20:17Z","timestamp":1668752417000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.1008695\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,18]]},"references-count":45,"alternative-id":["10.3389\/fimmu.2022.1008695"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2022.1008695","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,18]]},"article-number":"1008695"}}